Expanding Research and Treatment Options for Myeloproliferative Neoplasms (MPNs) | Houston, TX

What It Means for You or a Loved One


Saturday, October 24
MD Anderson Cancer Center
Houston, Texas


An audience of MPN patients and their caregivers joined us at a recent town meeting at the The University of Texas MD Anderson Cancer to hear the latest treatment and research news, inspiring stories of people living well with MPNs, tips for effective communication with a healthcare team and more. 

We are also planning events in other cities. If you haven’t already, please sign up for email updates so we can alert you when important and inspiring videos become available and when upcoming town meetings are scheduled.



Patient Folder


Understanding and Controlling MPN Symptoms

Dr. Rami Komrokji and Jane Williams discuss how activity, phlebotomy and communication can help alleviate certain symptoms associated with MPNs.


Do Genetic Mutations in MPNs Affect Treatment Choices?

Dr. Rami Komrokji discusses various genetic marker subsets of MPNs and how these alterations affect what type of treatment a patient should receive.


Can New MPN Treatments in Development Decrease Fibrosis?

“Can we interrupt the fibrotic process?” Dr. Srdan Verstovsek explains PRM-151 and how this anti-fibrotic therapy is being used to improve the quality of life for MPN patients.


What Makes Stem Cell Transplant Risky?

When an online viewer at one MPN town meeting asks the question, “What makes a stem cell transplant so risky?” Dr. Rami Komrokji shares an honest benefit vs. risk answer.


Are There Clinical Trial Therapies That High-Risk Myelofibrosis Patients Should Consider Before Transplant?

At a recent MPN town meeting, Dr. Srdan Verstovsek and Dr. Naval Daver from MD Anderson Cancer Center and Dr. Rami Komrokji from Moffitt Cancer discussed treatment considerations for myelofibrosis patients prior to stem cell transplant.


Sandra’s Story: Remaining Upbeat and Living an Active Lifestyle With PV

Sandra Johnson, a marathoner and bi- and tri-athlete, tells her story of being diagnosed first with essential thrombocythemia (ET) and then polycythemia vera (PV) and how she learned by the numbers how to be her own best advocate.


Optimism for the Future of MPN Treatment From a Clinical Investigator

Dr. Rami S. Komrokji, Clinical Director of the Malignant Hematology Department at Moffitt Cancer Center, shares his perspective on the future of research for myeloproliferative neoplasms (MPNs), new medications and clinical trials.


Expert Perspective: Encouraging MPN Research and Treatment Progress

Meet Dr. Laura Michaelis, Clinician and Clinical Researcher at Medical College of Wisconsin. She discusses the evolving landscape and scientific advantages in the field of MPNs including precision medicine, driver mutations and the developing role of social media.


Expert Perspective: Managing MPNs When Treatments Lose Effectiveness

Dr. Srdan Verstovsek from The University of Texas MD Anderson Cancer Center shares his perspective on disease management, genetic mutations, drug resistance and the future of research for myeloproliferative neoplasms (MPNs).


Showing 9 of 11 programs

Guest Presenters

Chief, Section for Myeloproliferative Neoplasms, Department of Leukemia; MPN Specialist

Assistant Professor, Department of Leukemia

Clinical Director of the Malignant Hematology Department

Clinician and Clinical Researcher

Advanced Practice Provider, Integrative Medicine Program

Patient Advocate

Patient Advocate


Host, Patient Power Co-Founder, Two-Time Cancer Survivor and Patient Advocate

Online Host, Patient Power Co-Founder, Caregiver and Patient Advocate

This town meeting was sponsored by Baxalta, Inc., CTI BioPharma, and the Patient Empowerment Network, which received an educational grant from Incyte Corporation. It was produced by Patient Power in partnership with The University of Texas MD Anderson Cancer Center. 






Page last updated on May 15, 2016